Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Characteristics and management of primary gastrointestinal non-Hodgkin's lymphoma

A uniform reporting system for primary gastrointestinal non-Hodgkin's lymphoma is needed to facilitate comparison of treatment results, according to research in the latest Journal of Clinical Oncology.

News image

fiogf49gjkf04

Researchers from Germany conducted two studies, in which they investigated the characteristics and management of patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL), between 1992 and 1996.

In the first, they obtained epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in 371 patients with PGI NHL.

Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not.

Of the patients, 75% had gastric NHL. Within the intestine, the small bowel and the ileocecal region were involved in 9% and 7% of the cases, respectively. Multiple GI involvement was 6.5%.

Approximately 90% of the GI NHL were in stages IE/IIE.

Aggressive NHL accounted for the majority, with a distinguishable pattern in several sites.

40% of PGL were of low-grade mucosa-associated lymphatic tissue type. One third of large-cell lymphomas had low-grade components. Most intestinal NHL were germinal-center lymphomas.

In gastric and ileocecal lymphoma, event-free and overall survival were significantly higher, as compared with the small intestine or multiple GI involvement.

In PGL, localized disease was prognostic for both event-free and overall survival. However, histologic grade only influenced event-free survival significantly.

The authors commented that PGI NHL are heterogeneous diseases. The number of localized PGL allowed the investigators to conduct detailed analyses, although larger studies are needed for stages III and IV, and for intestinal NHL.

A uniform reporting system for PGI NHL, in terms of definitions, and histologic and staging classifications, is needed to facilitate comparison of treatment results, they concluded.

5-year survival rates after PGI NHL treatment:
Conservative treatment 84%
Conservative treatment plus surgery 85%
Journal of Clinical Oncology

In the second study, the team focused on the combined surgical and conservative treatment (CSCT) versus conservative treatment (CT) alone for localized gastric lymphoma.

Patients with low-grade PGL were treated with extended-field (EF) radiotherapy (30 Gy).

In case of residual tumor after surgery or in case of CT only (in stage IIE after 6 cycles of cyclophosphamide, vincristine, and prednisone), an additional boost of 10 Gy was given.

All patients with high-grade PGL were treated with 4 (stage IE) or 6 (stage IIE) cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone. This was followed by EF radiotherapy (stage IE) or involved-field (IF) radiotherapy (stage IIE).

Radiotherapy dosage corresponded to low-grade NHL.

A total of 106 patients had CT only. The survival rate after 5 years was found to be 84%. It was influenced neither by patients' characteristics nor by stage or histologic grade.

Some 79 patients had CSCT. Their survival rate was 82%.

The team found that complete resection of the tumor was prognostic for the overall survival, as compared with incomplete resection.

Dr Peter Koch, of Münster, Germany, concluded on behalf of the group, "Although the study was not randomized, a stomach-conserving approach may be favored."

J Clin Oncol 2001; 19 (18): 3861-83
20 September 2001

Go to top of page Email this page Email this page to a colleague

 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management
 22 January 2018 
Improving symptoms in GERD
 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 04 January 2018 
Yoga vs low-FODMAP in IBS
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us